Wojciech Rogowski

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations

Pharmacy, Oncology, Pharmacotherapy +14

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 416 citations · Full text

Medicine, Oncology, Pharmacology +15

MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study

Tamas Hickish, Thierry André, Lucjan Wyrwicz et al. · The Lancet Oncology · 2017 · 160 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

Brian Rini, Cezary Szczylik, Nizar M. Tannir et al. · Cancer · 2012 · 110 citations · Full text

Medicine, Oncology, Pharmacology +15